Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 795 of 6351
-
Twice-Yearly shot could revolutionize HIV prevention for drug users
Prevention OngoingThe goals of this clinical study are to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for pre-exposure prophylaxis (PrEP) in people who inject drugs (PWID) in the United States (US). …
Phase 2 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated Aug 15, 2026 00:00 UTC
-
Can a simple blood test guide myeloma treatment and spare some patients from transplant?
Disease control Recruiting nowThis research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone…
Phase 2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a poop pill tame inflammation? new trial tests FMT for arthritis and bowel disease
Disease control Recruiting nowPURPOSE: The main purpose is to explore clinical efficacy and safety associated with capsule FMT (cFMT) performed in newly diagnosed, untreated patients with rheumatic and gastrointestinal chronic inflammatory diseases (CIDs). DESIGN AND METHODS: In this 1:1 double-blind, placeb…
Phase 2 • Sponsor: Odense University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for rare stomach cancer: drug combo targets tough mutations
Disease control OngoingThis is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon…
Phase 3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug combo aims to block cancer growth in RAS-Mutant tumors
Disease control OngoingThis phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New targeted drug shows promise for hard-to-treat stomach and pancreatic cancers
Disease control Recruiting nowThe purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Promising new pill targets rare cancer in phase 3 trial
Disease control CompletedThis study is open to adults with a type of cancer called dedifferentiated liposarcoma (DDLPS). They can join the study if their tumours are positive for MDM2. The purpose of this study is to find out whether a medicine called brigimadlin (BI 907828) is tolerated by and helps peo…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Could a lighter touch in IVF yield healthier embryos for women over 35?
Disease control Recruiting nowThis randomized trial was designed as a no-inferiority trial aiming to evaluate if the intensity of stimulation (a milder vs a more intense approach) may have an impact on the number of euploid embryos and the morpho kinetic parameters in advanced age women undergoing PGT-A with …
Phase 4 • Sponsor: Fundación Santiago Dexeus Font • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New cocktail aims to stamp out stubborn ovarian cancer cells
Disease control Recruiting nowTo find out if combining pembrolizumab, bevacizumab (or an equivalent biosimilar drug), and low-dose cyclophosphamide can help control high-grade ovarian cancer that has MRD after treatment. The safety of this treatment combination will also be studied.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug cocktail aims to tackle tough breast cancer
Disease control Recruiting nowThis phase II study is a clinical study to explore the efficacy and safety of SI-B003 monotherapy and BL-B01D1+SI-B003 combination therapy in patients with unresectable locally advanced or recurrent metastatic HER-2 negative breast cancer.
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Poop pills may shield stem cell patients from deadly immune attack
Prevention OngoingThis randomized placebo-controlled double-blind phase II trial tests whether fecal microorganism (microbiota) transplantation prevents severe acute graft versus host disease in adults undergoing allogeneic hematopoietic cell transplantation (HCT). Fecal microbiota transplantation…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Jul 22, 2026 00:00 UTC
-
New drug duo aims to shrink enlarged spleens in myelofibrosis patients
Disease control Recruiting nowThis is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets combined with TQB3617 Capsules in patients with intermediate- and high-risk Myelofibrosis.
Phase 1/2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for arthritis sufferers: experimental drug shows promise in Late-Stage trial
Disease control OngoingBrief Summary: This is a randomized, double-blind study comparing LNK01001 to placebo in Chinese participants with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and have an i…
Phase 3 • Sponsor: Lynk Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug aims to let sunlight-sensitive patients enjoy the sun longer
Symptom relief CompletedTo investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.
Phase 3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Can a Patient's own kidney cells slow kidney disease?
Disease control Recruiting nowThe purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).
Sponsor: Prokidney • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug shows promise in slowing lung scarring
Disease control OngoingThe study will evaluate the efficacy and safety of axatilimab in participants with IPF.
Phase 2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for kids with Crohn's: risankizumab trial launches
Disease control Recruiting nowCrohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately t…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Nasal spray may offer quick fix for Children's racing heart
Disease control Recruiting nowNODE-202 is a Phase 2, multicenter, multinational, single dose, open-label, 2-part, sequential design study in pediatric patients with an established diagnosis of paroxysmal supraventricular tachycardia (PSVT) presenting with a symptomatic episode of PSVT. In Part 1, at least 30…
Phase 2 • Sponsor: Milestone Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Lung cell therapy shows promise in IPF trial
Disease control CompletedIdiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease with injury of lung tissues. REGEND001 is a cell therapy product, made from bronchial basal cells with ability to regenerate lung tissue, is promising to IPF treatment. This is a multi-center, randomized…
Phase 2 • Sponsor: Regend Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug combo aims to shrink advanced bladder tumors
Disease control Recruiting nowThis phase II study is designed to explore the efficacy and safety of SI-B003 monotherapy and BL-B01D1+SI-B003 combination therapy in patients with locally advanced or metastatic urothelial carcinoma and other solid tumors.
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC